Inspire Investing
CLDX icon

Inspire Investing’s Celldex Therapeutics CLDX Stock Holding History

Inspire Investing’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$32 Hold
1
– – ﹤0.01% 1262
2026
Q2 		$37 Hold
1
– – ﹤0.01% 1246
2026
Q1 		$32 Hold
1
– – ﹤0.01% 1084
2025
Q4 		$27 Buy
+1
New +$26 ﹤0.01% 1094
2020
Q2 		– Sell
-178
Closed – – 538
2020
Q1 		$0 Buy
+178
New +$402 ﹤0.01% 751
2018
Q1 		– Sell
-28
Closed -$1K – 293
2017
Q4 		$1K Buy
+28
New +$1.2K ﹤0.01% 850

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TSP Capital Management Group
TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return
Mirador Capital Partners
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
Apella Capital
Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return
Overbrook Management Corp
Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return
Values First Advisors
Values First Advisors Gray, Tennessee $213M AUM 20.51% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Inspire Investing's CLDX Position: Q3 2026 in Review

Inspire Investing held its Celldex Therapeutics (CLDX) position steady in Q3 2026 at 1 share worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

Inspire Investing first reported a position in CLDX in Q4 2017 and has held it in 6 quarters since. The position peaked at $1K in Q4 2017. 29 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Inspire Investing held 1 share of Celldex Therapeutics worth $32 as of Q3 2026.
  • Inspire Investing left its Celldex Therapeutics share count unchanged in Q3 2026.
  • Celldex Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q3 2026, its #1262 holding.
  • Inspire Investing first reported a position in Celldex Therapeutics in Q4 2017 and has held it in 6 quarters since.
  • Inspire Investing's Celldex Therapeutics position peaked at $1K in Q4 2017.
  • 29 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Inspire Investing's 13F filing for Q3 2026, filed 22 Oct 2026.